Ipilimumab/nivolumabMyasthenia gravis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1917卷 / 1期

关键词：

D O I：

10.1007/s40278-022-20196-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：325 / 325

相关论文

共 50 条

[41] Ipilimumab/nivolumabAutoimmune demyelinating polyneuropathy and myasthenia gravis: case report
Reactions Weekly, 2022, 1917 (1) : 322 - 322
[42] Ipilimumab/nivolumabGuillain-Barre syndrome and myasthenia gravis: case report
Reactions Weekly, 2022, 1895 (1) : 230 - 230
[43] Ipilimumab/nivolumabMyocarditis with myositis and myasthenia gravis overlap syndrome: case report
Reactions Weekly, 2025, 2042 (1) : 241 - 241
[44] Ipilimumab/nivolumabAnti-striational antibodies in myasthenia gravis and myositis: case report
Reactions Weekly, 2021, 1880 (1) : 218 - 218
[45] NivolumabMyasthenia gravis, rheumatoid arthritis and fulminant type 1 diabetes mellitus: 2 case reports
Reactions Weekly, 2017, 1682 (1) : 234 - 234
[46] Ipilimumab/Methotrexate/NivolumabMyocarditis-myositis-myasthenia gravis overlap syndrome and hepatic toxicity: case report
Reactions Weekly, 2024, 2034 (1) : 184 - 184
[47] Ipilimumab/sargramostimDermatomyositis: case report
Reactions Weekly, 2016, 1603 (1) : 158 - 158
[48] Ipilimumab/pembrolizumabIleus: case report
Reactions Weekly, 2023, 1956 (1) : 287 - 287
[49] Ipilimumab/NivolumabMyocarditis: case report
Reactions Weekly, 2024, 2028 (1) : 253 - 253
[50] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2022, 1887 (1) : 396 - 396

← 1 2 3 4 5 →